Featured Publications
Clinical Outcomes and Immune Markers by Race in a Phase I/II Clinical Trial of Durvalumab Concomitant with Neoadjuvant Chemotherapy in Early-Stage TNBC.
Foldi J, Kahn A, Silber A, Qing T, Reisenbichler E, Fischbach N, Persico J, Adelson K, Katoch A, Chagpar A, Park T, Blanchard A, Blenman K, Rimm DL, Pusztai L. Clinical Outcomes and Immune Markers by Race in a Phase I/II Clinical Trial of Durvalumab Concomitant with Neoadjuvant Chemotherapy in Early-Stage TNBC. Clinical Cancer Research 2022, 28: 3720-3728. PMID: 35903931, PMCID: PMC9444984, DOI: 10.1158/1078-0432.ccr-22-0862.Peer-Reviewed Original ResearchConceptsImmune-related adverse eventsTriple-negative breast cancerNon-AA patientsEvent-free survivalPhase I/II clinical trialsClinical trialsNeoadjuvant chemotherapyOverall survivalAA patientsEarly-stage triple-negative breast cancerIncidence of irAEsPathologic complete response rateSignificant associationMultivariate logistic regression analysisTumor-infiltrating lymphocyte countsComplete response ratePrimary efficacy endpointPD-L1 statusProportional hazards modelLogistic regression analysisAfrican American womenEFS ratesNeoadjuvant immunotherapyEfficacy endpointAdverse eventsClinical impact of adjuvant radiation therapy delay after neoadjuvant chemotherapy in locally advanced breast cancer
Silva S, Pereira A, Marta G, de Barros Lima K, de Freitas T, Matutino A, de Azevedo Souza M, de Azevedo R, de Viveiros P, da Silva Lima J, Filassi J, de Andrade Carvalho H, Piato J, Mano M. Clinical impact of adjuvant radiation therapy delay after neoadjuvant chemotherapy in locally advanced breast cancer. The Breast 2017, 38: 39-44. PMID: 29223797, DOI: 10.1016/j.breast.2017.11.012.Peer-Reviewed Original ResearchConceptsPost-operative radiation therapyDisease-free survivalBetter disease-free survivalNeoadjuvant chemotherapyBreast cancerOverall survivalAdvanced breast cancerClinical stage IIIBetter overall survivalAdvanced BC patientsTherapy delayBC patientsClinical impactEarly initiationRadiation therapyStage IIIPatientsSurgeryOptimal timingWeeksChemotherapyFirm conclusionsCancerSurvivalInitiation
2017
Prophylactic Cranial Irradiation for Extensive-Stage Small-Cell Lung Cancer: A Retrospective Analysis
Matutino A, Mak M, Takahashi T, Bitton R, Nakazato D, Fraile N, Guimarães R, Gabrielli F, Vasconcelos K, de A. Carvalho H, de Castro G. Prophylactic Cranial Irradiation for Extensive-Stage Small-Cell Lung Cancer: A Retrospective Analysis. Journal Of Global Oncology 2017, 4: jgo.17.00059. PMID: 30241202, PMCID: PMC6181177, DOI: 10.1200/jgo.17.00059.Peer-Reviewed Original ResearchConceptsExtensive-stage small-cell lung cancerProphylactic cranial irradiationSmall cell lung cancerProgression-free survivalBrain metastasesOverall survivalCranial irradiationLung cancerBenefit of PCISymptomatic brain metastasesFirst-line settingSecond-line chemotherapyKaplan-Meier methodPlatinum-based chemotherapyCareful patient selectionBrain metastasis controlBaseline brainEligible patientsSystemic chemotherapyChemotherapy exposureProgressive diseasePatient selectionTherapeutic challengeDecreased incidencePatient survival